SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article. PM calculated as the ratio of the indirect effect (effect through the mediator) to the total effect (effect both through and not through the mediator).
c Satisfaction, concerns and palatability scores.
d PM calculated to be >100%; in instances with multiple mediators, because of the interaction between them, the PM may be calculated to be >100%.
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change not through the mediator(s). Results are reported as PM, ie the proportion of the total association between exposure and outcomes that is operationalized through the mediator(s) of interest, calculated as one minus the ratio of the association that does not go through the mediator, divided by the total association. Analytical variables were log transformed or square-root transformed for normality, as required.
A total of 154 patients had at least one PRO assessment over the study period and were included in the analyses. Among these patients, the average patient-reported adherence score mediated 66.6%
(P = 0.012) of the association between treatment and change in serum ferritin (Table 1) . Patient-reported adherence, satisfaction, concerns, palatability scores, and frequency of severe GI-related AEs together mediated 90.1% of the association (P = 0.014). In DT non-naïve patients, the PM by patient-reported adherence was 62.6% (P = 0.014),
and by patient-reported adherence and other PRO scores was 94.3%
(P = 0.012). In the DT non-naïve with thalassemia and thalassemia subgroups, similar trends were observed (Table 1 ).
In summary, these analyses found that PRO scores, specifically adherence, represent important mediators of the observed difference in serum ferritin reduction between the two treatment groups.
The PM was greatest among patients with prior experience with DT. One explanation, supported by a previous comparative analysis of iron chelation therapies, 3 is that patients with prior experience with DT have a reference frame for comparing the new FCT formulation with the standard formulation, and are better able to appreciate attributes of the new formulation.
This analysis is subject to several limitations. During ECLIPSE, a larger proportion of FCT patients received a higher-than-recommended dose or were not dose adjusted during management of AEs, which could have contributed to the observed serum ferritin reduction. 5 In addition, serum ferritin levels in the deferasirox FCT arm were higher than in the DT arm at baseline (2983 vs 2485 ng/mL). Furthermore, these results may not be generalizable outside the context of ECLIPSE because of the stringent inclusion/exclusion criteria. Although multivariate models were used to adjust for baseline covariates, the effect estimates between treatment group and serum ferritin reduction should be interpreted as associations, and the estimates of mediation by PROs should be interpreted as statistical mediation and not necessarily as causal.
In conclusion, this post hoc analysis supports the importance of considering PROs in determining the efficacy of chelation therapy for iron overload. Owing to its better palatability and ease of use, deferasirox FCT may be a superior therapy to DT for some patients with iron overload by increasing adherence to therapy. 
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